FLOT chemotherapy favored in surgery-eligible stomach and junction cancers
For operable stomach or stomach–food-pipe junction cancers, FLOT chemotherapy around surgery favored survival comparisons. Evidence about the value of additional treatments remained uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For patients with operable stomach or junction adenocarcinoma, FLOT chemotherapy around surgery showed better disease-free and overall survival than surgery alone or the chemotherapy-and-radiation regimen CROSS. Limited data did not establish additional survival benefit from adding radiation to FLOT. The analysis also did not establish superiority over FLOT for the pembrolizumab-containing chemotherapy regimen.
Direct comparisons were limited, and some evidence comes through the treatment network. The abstract gives no follow-up duration or absolute survival gains, and identifies limited data on adding chemoradiation to FLOT.
What researchers found
Survival without disease
FLOT around surgery versus surgery alone: hazard ratio 0.48, 95% confidence interval 0.38–0.60; follow-up duration was not reported.
What a network comparison means
A network meta-analysis connects trials of different treatments, allowing comparisons through shared alternatives when direct trials are limited. This can broaden the comparison, but treatment rankings need to be read alongside the available evidence.
Understanding the survival result
Disease-free survival tracks remaining free of disease; overall survival tracks remaining alive. A hazard ratio compares event rates over follow-up. It does not state an absolute survival gain or how much longer an individual would live.
The original publication
Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.
Anjum MU, Naqvi SAA, Jajja SA et al.
Oncologist · 2025
- PubMed ID
- 40653807
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.